Genetic Signatures

Genetic Signatures Limited – Annual Report 2020 Chairman’s Letter ................................3 CEO Report ...........................................4 FY20 Results ........................................5 Commercialisation Update.................6 EasyScreen TM Kits .............................11 Market Oportunities ..........................12 Personnel ...........................................16 Financial Report 2020.......................19 Contents Our Purpose &Vision Genetic Signatures is a molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary 3base™ platform technology. Our 3base™ technology (the cornerstone of our EasyScreen™ Pathogen Detection Kits ), reduces the genetic complexity of infection detection in molecular testing. Our tests enable hospital and pathology facilities to use standard equipment and procedures to more accurately screen for a wide array of infectious diseases (pathogens) and deliver enhanced results in hours, not days, as compared to traditional methods. Our aim is to become a global leader in the supply of diagnostic solutions for the rapid detection of infectious diseases. Timely, accurate diagnosis improves patient outcomes and allows the implementation of appropriate infection control measures that reduce costs and save lives. Through minimising work and maximising results, Genetic Signatures drives customer and shareholder value whilst improving community health across the globe.

RkJQdWJsaXNoZXIy MTI3ODI1